indazoles has been researched along with Lung Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domoto, H; Hashiguchi, MH; Hiroshima, Y; Kagyo, J; Kato, T; Matsuzaki, T; Nakahara, Y; Sato, T; Shiomi, T; Watanabe, R; Yokose, T | 1 |
| Calogero, A; Ciccone, AM; De Falco, E; Ibrahim, M; Menna, C; Pacini, L; Petrozza, V; Puca, R; Rendina, EA; Ruggieri, P; Scafetta, G | 1 |
2 other study(ies) available for indazoles and Lung Adenocarcinoma
| Article | Year |
|---|---|
A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Topics: Adenocarcinoma of Lung; Adult; Benzamides; Crizotinib; Female; Gene Rearrangement; Genomics; Humans; Indazoles; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2021 |
Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Axitinib; Cell Movement; Cell Survival; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Indazoles; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Protein Kinase Inhibitors; Radiography; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation; Vascular Endothelial Growth Factor A | 2014 |